{"organizations": [], "uuid": "e21f843ba5239d7d79a664958774c9b8c2357002", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180509.html", "section_title": "Archive News &amp; Video for Wednesday, 09 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-cosmo-pharmaceuticals-says-receive/brief-cosmo-pharmaceuticals-says-receives-letter-from-fda-on-methylene-blue-mmx-idUSFWN1SG1H9", "country": "US", "domain_rank": 408, "title": "BRIEF-Cosmo Pharmaceuticals Says Receives Letter From FDA On Methylene Blue MMX", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.152, "site_type": "news", "published": "2018-05-09T23:57:00.000+03:00", "replies_count": 0, "uuid": "e21f843ba5239d7d79a664958774c9b8c2357002"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-cosmo-pharmaceuticals-says-receive/brief-cosmo-pharmaceuticals-says-receives-letter-from-fda-on-methylene-blue-mmx-idUSFWN1SG1H9", "ord_in_thread": 0, "title": "BRIEF-Cosmo Pharmaceuticals Says Receives Letter From FDA On Methylene Blue MMX", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "fda on methylene blue mmx", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "cosmo pharmaceuticals nv", "sentiment": "negative"}, {"name": "cosmo pharmaceuticals", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 9 (Reuters) - Cosmo Pharmaceuticals NV:\n* RECEIVED A LETTER FROM FDA AS PART OF THEIR ONGOING REVIEW OF COMPANYâ€™S NEW DRUG APPLICATION\n* AGENCY HAS IDENTIFIED DEFICIENCIES * COSMO PHARMACEUTICALS - DEFICIENCIES PRECLUDE CONTINUATION OF DISCUSSION OF LABELING AND POST MARKETING REQUIREMENTS AT THIS TIME Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-09T23:57:00.000+03:00", "crawled": "2018-05-10T17:48:09.013+03:00", "highlightTitle": ""}